Articles by Cynthia Challener, PhD - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Cynthia Challener, PhD

QbD in API Manufacturing

With a quality-by-design approach, robust processes consistently can help deliver quality product.
Sep 2, 2014

With a quality-by-design approach, robust processes consistently can help deliver quality product.

Asymmetric Synthesis Continues to Advance

A survey of the recent literature reveals numerous advances in asymmetric chemocatalysis.
Sep 2, 2014

A survey of the recent literature reveals numerous advances in asymmetric chemocatalysis.

African Biopharma Market Presents Long-term Opportunities

Sep 1, 2014

Biopharma companies seeking to leverage opportunities in African market must adopt the right strategy to achieve success.

Taking Action on Elemental Impurities

Changing regulations are impacting the identification and monitoring of variable materials in excipients.
Sep 1, 2014

Changing regulations are impacting the identification and monitoring of variable materials in excipients.

Supply Chain Security Tops Concerns for Biopharma Raw Materials

Sep 1, 2014

Biopharma are looking to reduce risk, increase performance, and optimize productivity in raw material development.

Exploring a New Approval Process for Continued Excipient Innovation

New excipients and improvements to existing excipients are needed to facilitate access to new drugs for patients.
Sep 1, 2014

New excipients and improvements to existing excipients are needed to facilitate access to new drugs for patients.

Need for Supply Chain Transparency is Acute

Biopharma manufacturers must reduce risk in their complex supply chains and establish effective monitoring and control systems.
Sep 1, 2014

Biopharma manufacturers must reduce risk in their complex supply chains and establish effective monitoring and control systems.

Acute Need for Supply Chain Transparency

Biopharma manufacturers must reduce the risk in their complex supply chains
Aug 4, 2014

Biopharma manufacturers must reduce the risk in their complex supply chains

Steady Progress Toward Continuous Flow API Synthesis

The pharma industry makes slow, but steady moves toward commercial-scale continuous processes for small-molecule API manufacturing.
Aug 4, 2014

The pharma industry makes slow, but steady moves toward commercial-scale continuous processes for small-molecule API manufacturing.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
FindPharma Custom Search
Click here